Who Paid My Doc
Steven Marso
Interventional Cardiology Kansas City, MO Medical Doctor
NPI 1528026374 CMS profile 250711
2330 E Meyer Blvd, Suite 509, Kansas City, MO 64132
General payments
$41,510
Research payments
$5,250
Ownership & investment interest
$0
Research they led as principal investigator
$879,236
Through program year 2024, Steven Marso of Kansas City, MO is reported in the CMS Open Payments database as having received $41,510 across 134 general payments and $5,250 in research payments paid to them. Separately, studies naming them as principal investigator received $879,236 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 86th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $66 | 3 | |
| 2023 | General | $429 | 26 | |
| 2022 | General | $8,865 | 25 | |
| 2021 | General | $5,993 | 21 | |
| 2020 | General | $190 | 5 | |
| 2020 | Research | $5,250 | 2 | |
| 2019 | General | $25,968 | 54 |
Beside peers
- Steven Marso
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Steven Marso were reported at $0. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Steven Marso | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $25,968 | $1,097 | $329–$3,048 | $163 |
| 2020 | $190 | $473 | $161–$1,480 | $114 |
| 2021 | $5,993 | $677 | $233–$1,827 | $132 |
| 2022 | $8,865 | $978 | $333–$2,724 | $149 |
| 2023 | $429 | $1,136 | $382–$2,986 | $160 |
| 2024 | $66 | $1,181 | $395–$3,326 | $164 |
| 2025 | $0 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
136 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in Missouri
Joshua Stolker
Interventional Cardiology · Washington, MO
John Lasala
Interventional Cardiology · Saint Louis, MO
Harvey Serota
Interventional Cardiology · Saint Louis, MO
Jasvindar Singh
Interventional Cardiology · Saint Louis, MO
Gerald Mancuso
Interventional Cardiology · Kansas City, MO
James Grantham
Interventional Cardiology · Kansas City, MO
Related records
Interventional Cardiology in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.